These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12670744)

  • 1. Diminished renal kallikrein responses to mineralocorticoid stimulation in African Americans: determinants of an intermediate phenotype for hypertension.
    Wong CM; O'Connor DT; Martinez JA; Kailasam MT; Parmer RJ
    Am J Hypertens; 2003 Apr; 16(4):281-9. PubMed ID: 12670744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal kallikrein excretion: role of ethnicity, gender, environment, and genetic risk of hypertension.
    Song CK; Martinez JA; Kailasam MT; Dao TT; Wong CM; Parmer RJ; O'Connor DT
    J Hum Hypertens; 2000 Jul; 14(7):461-8. PubMed ID: 10918552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial differences in renal kallikrein excretion: effect of the ovulatory cycle.
    Kailasam MT; Martinez JA; Cervenka JH; Yen SS; O'connor DT; Parmer RJ
    Kidney Int; 1998 Nov; 54(5):1652-8. PubMed ID: 9844141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships among urinary kallikrein, mineralocorticoids and human hypertensive disease.
    Margolius HS; Horwitz D; Pisano JJ; Keiser HR
    Fed Proc; 1976 Feb; 35(2):203-6. PubMed ID: 1248655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary kallikrein excretion in essential and mineralocorticoid hypertension.
    Holland OB; Chud JM; Braunstein H
    J Clin Invest; 1980 Feb; 65(2):347-56. PubMed ID: 7356684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating kallikreins in normotensive and hypertensive humans: effects of mineralocorticoid administration.
    Ohman KP
    Blood Press; 1997 Jul; 6(4):214-22. PubMed ID: 9296308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of restriction of sodium or administration of fludrocortisone on parotid salivary kallikrein in man.
    Horwitz D; Proud D; Lawton WJ; Yates KN; Highet P; Pisano JJ; Keiser HR
    J Lab Clin Med; 1982 Jul; 100(1):146-54. PubMed ID: 6919568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone.
    Bamberg K; William-Olsson L; Johansson U; Jansson-Löfmark R; Hartleib-Geschwindner J
    J Renin Angiotensin Aldosterone Syst; 2019; 20(1):1470320319827449. PubMed ID: 30813831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal kallikrein-kinin system and prostaglandin in hypertension: their relation to renin-angiotensin-aldosterone system.
    Abe K; Yasujima M; Chiba S; Sato M; Irokawa N; Imai Y; Yoshinaga K
    Adv Exp Med Biol; 1979; 120B():487-501. PubMed ID: 517244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of mineralocorticoid activity on transtubular potassium gradient, urinary [K]/[Na] ratio, and fractional excretion of potassium.
    Chacko M; Fordtran JS; Emmett M
    Am J Kidney Dis; 1998 Jul; 32(1):47-51. PubMed ID: 9669423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal and renal excretion of potassium in African-Americans and White Americans.
    Rosa RM; De Jesus E; Sperling K; Suh A; Gmurczyk A; Myrie KA; Rosner K; Lerma E; Yu W; Breuer R; Young JB
    J Hypertens; 2012 Dec; 30(12):2373-7. PubMed ID: 23111624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary kallikrein and plasma renin activity as determinants of renal blood flow. The influence of race and dietary sodium intake.
    Levy SB; Lilley JJ; Frigon RP; Stone RA
    J Clin Invest; 1977 Jul; 60(1):129-38. PubMed ID: 874078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Selected components of the kallikrein-kinin system and of the renin-angiotensin-aldosterone system in offspring of parents with hypertension].
    Marzecka J
    Ann Acad Med Stetin; 1996; 42():123-38. PubMed ID: 9199117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the renal kallikrein gene in mineralocorticoid-treated and genetically hypertensive rats.
    Fuller PJ; Clements JA; Nikolaidis I; Hiwatari M; Funder JW
    J Hypertens; 1986 Aug; 4(4):427-33. PubMed ID: 3639907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial differences in potassium disposal.
    Suh A; DeJesus E; Rosner K; Lerma E; Yu W; Young JB; Rosa RM
    Kidney Int; 2004 Sep; 66(3):1076-81. PubMed ID: 15327401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma mineralocorticoids, plasma renin, and urinary kallikrein in salt-sensitive and salt-resistant rats.
    Rapp JP; Tan SY; Margolius HS
    Endocr Res Commun; 1978; 5(1):35-41. PubMed ID: 710365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dietary potassium and race on urinary excretion of kallikrein and aldosterone in man.
    Horwitz D; Margolius HS; Keiser HR
    J Clin Endocrinol Metab; 1978 Aug; 47(2):296-9. PubMed ID: 263797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary kallikrein in normotensive subjects and in patients with essential hypertension.
    Zschiedrich H; Fleckenstein P; Geiger R; Fink E; Sinterhauf K; Philipp T; Distler A; Wolff HP
    Clin Exp Hypertens (1978); 1980; 2(3-4):693-708. PubMed ID: 7000466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary kallikrein in normal renin essential hypertension.
    Lawton WJ; Fitz AE
    Circulation; 1977 Nov; 56(5):856-9. PubMed ID: 912848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of acute mineralocorticoid and glucocorticoid receptor blockade on the excretion of an acute potassium load in healthy humans.
    van Buren M; Boer P; Koomans HA
    J Clin Endocrinol Metab; 1993 Oct; 77(4):902-9. PubMed ID: 8408463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.